113 related articles for article (PubMed ID: 29792122)
1. Drug cost avoidance in clinical trials of breast cancer.
Mañes-Sevilla M; Romero-Jiménez R; Herranz-Alonso A; Sánchez-Fresneda M; Gonzalez-Haba E; Collado-Borrel R; Benedi-González J; Sanjurjo-Sáez M
J Oncol Pharm Pract; 2019 Jul; 25(5):1099-1104. PubMed ID: 29792122
[TBL] [Abstract][Full Text] [Related]
2. Drug Cost Avoidance in Prostate Cancer Clinical Trials.
Calvin-Lamas M; Portela-Pereira P; Rabuñal-Alvarez MT; Martinez-Breijo S; Martín-Herranz MI; Gómez-Veiga F
Actas Urol Esp; 2015 Nov; 39(9):553-7. PubMed ID: 26071987
[TBL] [Abstract][Full Text] [Related]
3. Drug cost avoidance resulting from cancer clinical trials.
Bredin C; Eliasziw M; Syme R
Contemp Clin Trials; 2010 Nov; 31(6):524-9. PubMed ID: 20840876
[TBL] [Abstract][Full Text] [Related]
4. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan.
Shen LJ; Chou H; Huang CF; Chou GM; Chan WK; Wu FL
Contemp Clin Trials; 2011 Jul; 32(4):485-91. PubMed ID: 21530679
[TBL] [Abstract][Full Text] [Related]
5. Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology setting.
Truong K; Kwan YL; Nigro L; Huseincehajic A; Trotman J
Intern Med J; 2019 Sep; 49(9):1092-1098. PubMed ID: 30907047
[TBL] [Abstract][Full Text] [Related]
6. Drug cost savings in phase III hematological oncology clinical trials in a university hospital.
Herledan C; Ranchon F; Schwiertz V; Baudouin A; Karlin L; Ghesquières H; Salles G; Rioufol C
Hematol Oncol; 2020 Oct; 38(4):576-583. PubMed ID: 32469095
[TBL] [Abstract][Full Text] [Related]
7. Economic benefits of investigational drug services at an academic institution.
LaFleur J; Tyler LS; Sharma RR
Am J Health Syst Pharm; 2004 Jan; 61(1):27-32. PubMed ID: 14725117
[TBL] [Abstract][Full Text] [Related]
8. Costs and savings of investigational drug services.
McDonagh MS; Miller SA; Naden E
Am J Health Syst Pharm; 2000 Jan; 57(1):40-3. PubMed ID: 10630555
[TBL] [Abstract][Full Text] [Related]
9. The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure.
Gasperoni L; Cafaro A; Ferretti E; Di Iorio V; Nanni O; Masini C
Eur J Hosp Pharm; 2023 Mar; 30(2):96-100. PubMed ID: 35577545
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of drug cost reduction resulting from the free supply of investigational drugs].
Corvaisier S; Ferry S; Rochefort F
Therapie; 2003; 58(4):353-60. PubMed ID: 14679675
[TBL] [Abstract][Full Text] [Related]
11. Economic advantage of pharmacogenomics - clinical trials with genetic information.
Ohashi W; Mizushima H; Tanaka H
Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
[TBL] [Abstract][Full Text] [Related]
12. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy.
Grossi F; Genova C; Gaitan ND; Dal Bello MG; Rijavec E; Barletta G; Sini C; Donato C; Beltramini S; Pronzato P; Porcile G; Boccardo F; Walzer S
Lung Cancer; 2013 Aug; 81(2):236-40. PubMed ID: 23648072
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of drug cost savings related to clinical trials from the perspective of a university hospital.
Perrier Q; Minoves M; Cerana S; Reymond F; Ducki C; Decaens T; Lehmann A; Bedouch P
Eur J Hosp Pharm; 2023 May; ():. PubMed ID: 37248032
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials and drug cost savings for Italian health service.
D'Ambrosio F; De Feo G; Botti G; Capasso A; Pignata S; Maiolino P; Triassi M; Nardone A; Perrone F; Piezzo M; Grimaldi AM; Palazzo I; De Stasio I; D'Aniello R; Morabito A; Pascarella G
BMC Health Serv Res; 2020 Nov; 20(1):1089. PubMed ID: 33243262
[TBL] [Abstract][Full Text] [Related]
15. Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-2010).
Liniker E; Harrison M; Weaver JM; Agrawal N; Chhabra A; Kingshott V; Bailey S; Eisen TG; Corrie PG
Br J Cancer; 2013 Oct; 109(8):2051-7. PubMed ID: 24064969
[TBL] [Abstract][Full Text] [Related]
16. Conducting clinical trials-costs, impacts, and the value of clinical trials networks: A scoping review.
Bentley C; Cressman S; van der Hoek K; Arts K; Dancey J; Peacock S
Clin Trials; 2019 Apr; 16(2):183-193. PubMed ID: 30628466
[TBL] [Abstract][Full Text] [Related]
17. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach.
Hamblin S; Rumbaugh K; Miller R
J Trauma Acute Care Surg; 2012 Dec; 73(6):1484-90. PubMed ID: 23064610
[TBL] [Abstract][Full Text] [Related]
18. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.
Counterweight Project Team
J Health Serv Res Policy; 2008 Jul; 13(3):158-66. PubMed ID: 18573765
[TBL] [Abstract][Full Text] [Related]
19. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.
Tang PA; Hay AE; O'Callaghan CJ; Mittmann N; Chambers CR; Pater JL; Leighl NB
Curr Oncol; 2016 Feb; 23(Suppl 1):S7-S13. PubMed ID: 26985151
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
